

Table 1. Patient Characteristics

	Favorable remodelers (n=10)	Adverse Remodelers (n=11)	P-value
<i>Demographics</i>			
Age, years	58.4 ± 11.3	59.7 ± 8.9	0.77
Female sex, n (%)	3 (30)	4 (36)	0.77
White race, n (%)	7 (70)	8 (73)	0.9
Body mass index, kg/m ²	28.7 ± 7.3	30.4 ± 4.6	0.52
<i>Medical History</i>			
Prior myocardial infarction, n (%)	4 (40)	7 (64)	0.3
Hypercholesterolemia, n (%)	8 (80)	7 (64)	0.43
Diabetes mellitus, n (%)	2 (20)	3 (27)	0.71
Hypertension, n (%)	7 (70)	8 (73)	0.9
Smoking, n (%)	6 (60)	6 (55)	0.81
<i>Medications</i>			
Beta-blocker, n (%)	8 (80)	10 (91)	0.5
ACE inhibitor or ARB, n (%)	9 (90)	7 (64)	0.17
ASA, n (%)	9 (90)	11 (100)	0.31
Statin, n (%)	10 (100)	11 (100)	1.00
omega-3 fatty acids (%)	3 (30)	2 (18)	0.55
<i>CMR characteristics</i>			
LVESVI (initial), mL/m ²	36.1 ± 7.6	32.2 ± 7.1	0.23
LVESVI (6mo followup), mL/m ²	25 ± 6.2	43.9 ± 9.6	3.97E-05
Δ LVESI (%)	- 30.4	+ 37	6.85E -11
LVEF (initial), %	58 ± 6.0	58.2 ± 4.9	0.96
LVEF (6 mo followup), %	63.1 ± 6.0	53.2 ± 4.8	0.0005
Δ LVEF (%)	+ 0.09	- 0.08	0.0005